The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular diagnosis with the 92-gene assay (92-GA) and decision-impact on treatment: Final results from a prospective, multi-disciplinary study.
 
Sachdev P. Thomas
Honoraria - Celgene
Speakers' Bureau - Boehringer Ingelheim; Genentech/Roche; Pharmacyclics
Research Funding - bioTheranostics (Inst)
 
Lauren Jacobson
Honoraria - bioTheranostics
Research Funding - bioTheranostics (Inst)
 
Fadi S. Braiteh
Honoraria - Amgen; BIND Biosciences; Caris Life Sciences; Dendreon; Foundation Medicine; HERON; Incyte; Insys Therapeutics; MolecularHealth; Novartis; Pfizer; Saladax Biomedical; Sanofi
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Genomic Health; Incyte; Insys Therapeutics; Myriad Pharmaceuticals; Novartis; Pfizer; Sanofi
Research Funding - Abbvie (Inst); Abbvie (Inst); Active Biotech (Inst); Active Biotech (Inst); Amgen (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); BIND Biosciences (Inst); BIND Biosciences (Inst); Biomarin (Inst); Biomarin (Inst); bioTheranostics (Inst); bioTheranostics (Inst); BN ImmunoTherapeutics (Inst); BN ImmunoTherapeutics (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celgene (Inst); Cell Therapeutics (Inst); Cell Therapeutics (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Dendreon (Inst); Endocyte (Inst); Endocyte (Inst); Exelixis (Inst); Exelixis (Inst); Foundation Medicine (Inst); Foundation Medicine (Inst); Genomic Health (Inst); Genomic Health (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Halozyme (Inst); HERON (Inst); HERON (Inst); ImClone Systems (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Insys Therapeutics (Inst); Insys Therapeutics (Inst); Janssen (Inst); Janssen (Inst); Lilly (Inst); Lilly (Inst); MEI Pharma (Inst); MEI Pharma (Inst); Merrimack (Inst); Merrimack (Inst); Millennium (Inst); Millennium (Inst); MolecularHealth (Inst); MolecularHealth (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Plexxikon (Inst); Plexxikon (Inst); PSMA Development Company (Inst); PSMA Development Company (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Saladax Biomedical (Inst); Saladax Biomedical (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Viamet Pharmaceuticals (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Foundation Medicine; Genomic Health; Gilead Sciences; HERON; Incyte; Lilly; MolecularHealth; Pfizer; Roche/Genentech; Saladax Biomedical; Sanofi
 
Anthony R. Victorio
Research Funding - bioTheranostics (Inst)
 
Karen Ann Cherkis
Employment - bioTheranostics
Stock and Other Ownership Interests - bioTheranostics
 
Theresa N. Operana
Employment - bioTheranostics
Stock and Other Ownership Interests - bioTheranostics
 
Nichole Renee Blatner
Employment - bioTheranostics
Stock and Other Ownership Interests - bioTheranostics
 
Brock Schroeder
Employment - bioTheranostics
Stock and Other Ownership Interests - bioTheranostics
 
Catherine A. Schnabel
Employment - bioTheranostics
Stock and Other Ownership Interests - bioTheranostics